What is EicOsis?
EicOsis is a biopharmaceutical company dedicated to pioneering novel therapies for chronic pain and inflammation. Their core strategy involves targeting the soluble Epoxide Hydrolase (sEH) enzyme, a pathway believed to be crucial in restoring the body's innate healing mechanisms. The company is addressing a critical unmet need for non-addictive pain management solutions, a stark contrast to the prevalent opioid crisis. EicOsis's lead drug candidate is currently advancing through Phase 1 clinical trials, with a specific focus on alleviating neuropathic pain and other inflammatory conditions. The company's commitment lies in enhancing patient quality of life through its unique therapeutic approach.
How much funding has EicOsis raised?
EicOsis has raised a total of $4M across 1 funding round:
Private Equity
$4M
Private Equity (2016): $4M, investors not publicly disclosed
What's next for EicOsis?
The recent major strategic investment signals a pivotal moment for EicOsis, likely enabling the company to accelerate its clinical development pipeline and potentially expand its research into other inflammatory diseases. This infusion of capital is expected to support the progression of its lead candidate through further clinical trial phases, moving closer to potential market approval. EicOsis's focus on non-addictive pain relief positions it strategically within a market actively seeking alternatives to traditional pain medications. Future endeavors may include strategic partnerships or further funding rounds to support commercialization efforts.
See full EicOsis company page
